1-3 of 3
Stuart M. Lichtman
Close
Sort by
Journal Articles

Greater Total Dose and Duration of Treatment with Bortezomib Are Associated with Higher Incidence of Chalazion and Other Ocular Side Effects

Karuna Ganesh, MBBChir, PhD, Connie Batlevi, MD PhD, Zhigang Zhang, PhD, Hani Hassoun, MD, Nikoletta Lendvai, MD PhD, Heather Landau, MD, Craig H. Moskowitz, MD, Philip Caron, MD PhD, Robert Motzer, MD, Sergio A Giralt, MD, Paul Hamlin, MD, Stuart M. Lichtman, MD, Matthew J. Matasar, MD MS, Carol S Portlock, MD, Neerav Shukla, MD, Carol Wasserheit-Lieblich, MD, Andrew D. Zelenetz, MD PhD, John F. Gerecitano, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3487.
https://doi.org/10.1182/blood.V124.21.3487.3487
Published: 2014
Journal Articles

Renal Impairment and the Use of Bisphosphonates in Patients with Multiple Myeloma: Retrospective Analysis of 114 Patients with Respect to Age and Other Clinical Characteristics.

Sam Mazj, MD, Stuart M. Lichtman, MD.
Journal: Blood
Blood (2004) 104 (11): 4918.
https://doi.org/10.1182/blood.V104.11.4918.4918
Published: 2004
Journal Articles

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia: Presented in part at the 40 th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4-8, 1998.

Rajendra N. Damle, Tarun Wasil, Franco Fais, Fabio Ghiotto, Angelo Valetto, Steven L. Allen, Aby Buchbinder, Daniel Budman, Klaus Dittmar, Jonathan Kolitz, Stuart M. Lichtman, Philip Schulman, Vincent P. Vinciguerra, Kanti R. Rai, Manlio Ferrarini, Nicholas Chiorazzi
Journal: Blood
Blood (1999) 94 (6): 1840–1847.
https://doi.org/10.1182/blood.V94.6.1840
Published: 1999